Cowen and Company restated their buy rating on shares of Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) in a research note released on Thursday.

AERI has been the subject of several other research reports. Needham & Company LLC reaffirmed a buy rating and issued a $65.00 price objective on shares of Aerie Pharmaceuticals in a research note on Sunday, September 17th. Canaccord Genuity set a $65.00 price objective on Aerie Pharmaceuticals and gave the company a buy rating in a research note on Wednesday, August 16th. BidaskClub downgraded Aerie Pharmaceuticals from a sell rating to a strong sell rating in a research note on Saturday, June 17th. Cantor Fitzgerald reaffirmed an overweight rating and issued a $62.00 price objective (up previously from $56.00) on shares of Aerie Pharmaceuticals in a research note on Thursday, July 20th. Finally, Mizuho reaffirmed a buy rating and issued a $70.00 price objective on shares of Aerie Pharmaceuticals in a research note on Monday, October 2nd. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and eleven have issued a buy rating to the company. The stock currently has an average rating of Buy and a consensus target price of $66.62.

Shares of Aerie Pharmaceuticals (NASDAQ AERI) opened at 52.65 on Thursday. The firm’s market cap is $1.91 billion. Aerie Pharmaceuticals has a 12 month low of $32.05 and a 12 month high of $61.30. The stock’s 50 day moving average is $54.41 and its 200 day moving average is $50.31.

Aerie Pharmaceuticals (NASDAQ:AERI) last released its quarterly earnings data on Tuesday, August 1st. The company reported ($0.82) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.84) by $0.02. Analysts forecast that Aerie Pharmaceuticals will post ($2.59) EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This piece of content was posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece of content on another publication, it was illegally stolen and republished in violation of United States & international trademark & copyright law. The correct version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/10/09/cowen-and-company-reaffirms-buy-rating-for-aerie-pharmaceuticals-inc-aeri.html.

Large investors have recently added to or reduced their stakes in the business. Quantbot Technologies LP acquired a new stake in Aerie Pharmaceuticals during the 1st quarter valued at approximately $107,000. Ameritas Investment Partners Inc. acquired a new stake in Aerie Pharmaceuticals during the 1st quarter valued at approximately $108,000. BNP Paribas Arbitrage SA increased its position in Aerie Pharmaceuticals by 2,711.4% during the 2nd quarter. BNP Paribas Arbitrage SA now owns 3,711 shares of the company’s stock valued at $195,000 after purchasing an additional 3,579 shares during the period. BlueCrest Capital Management Ltd acquired a new stake in Aerie Pharmaceuticals during the 1st quarter valued at approximately $202,000. Finally, Amalgamated Bank acquired a new stake in Aerie Pharmaceuticals during the 2nd quarter valued at approximately $204,000. 94.64% of the stock is owned by institutional investors and hedge funds.

Aerie Pharmaceuticals Company Profile

Aerie Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s product candidates include Rhopressa (netarsudil ophthalmic solution) 0.02% (Rhopressa), and Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% (Roclatan).

Analyst Recommendations for Aerie Pharmaceuticals (NASDAQ:AERI)

Receive News & Stock Ratings for Aerie Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.